Tag: pipeline

Crescent Biopharma to Present at June Investor Conferences

WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in June:

Mayo Clinic and Microsoft collaborate to develop a frontier AI model for healthcare

Collaboration aims to expand access to Mayo Clinic's trusted healthcare expertise and improve patient and clinician experiences ROCHESTER, Minn., and REDMOND, Wash., June 2, 2026 /PRNewswire/...

Layne’s Chicken Fingers to Open Landmark 50th Restaurant in Lubbock Amid Rapid Nationwide Expansion

Texas-born chicken finger franchise will celebrate milestone opening with Free Layne's for a Year giveaways, Texas Tech NIL partnership and continued nationwide growth momentum.LUBBOCK,...

Cielo Waste Solutions to Present Project Nahoonai at ICAO Aviation Climate Week 2026

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO THE UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

Victoria’s Secret & Co. Reports First Quarter 2026 Results

REYNOLDSBURG, Ohio, June 02, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSXY) today reported financial results for the first quarter ended May 2, 2026.

Recycled Plastics Market worth $161.50 billion by 2033 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 2, 2026 /PRNewswire/ -- According to MarketsandMarkets, "Recycled Plastics Market by Source (Bottles, Fibers, Films, Foams), Process, Plastic Type (PET, PP,...

Global Waste-derived Pyrolysis Oil Market Report 2026 | Asia Pacific Leads Demand While Shell, BASF and Agilyx Compete in Circular Polymer Feedstock

NEWARK, Del., June 2, 2026 /PRNewswire/ -- According to the latest market analysis by Future Market Insights, the global waste-derived pyrolysis oil market is gaining momentum as...

DEEPX Announces Global Physical AI Mass Production Partnership with AAEON at COMPUTEX 2026

DEEPX ultra-low-power NPUs to be integrated into AAEON's industrial computing lineup, accelerating the deployment of commercial Physical AI across global industries.TAIPEI, June 2, 2026...

CPP Investments Partners with BlueCove to Enter Hospitality Sector in Korea

SEOUL, South Korea, June 2, 2026 /CNW/ - Canada Pension Plan Investment Board (CPP Investments) and BlueCove Investment (BlueCove), a Korean hospitality-focused asset manager,...

Recharge Power and Energy Decarb Launch Joint Venture Targeting Australia’s PV and BESS Market

TAIPEI, June 2, 2026 /PRNewswire/ -- Recharge Power (7921-TW), a pioneer and market leader in Taiwan's battery energy storage systems (BESS) industry, today announced...

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPipeline

Apollo Funds Complete Sale of ALTEMIRA, Leading Pan-Asian Aluminum Packaging Company

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IMMP

Lotus opens orders for Eletre X in mainland Europe